Differential in vitro interactions of a series of clinically useful topoisomerase-interacting compounds with the cleavage/religation activity of the human topoisomerase IIα and IIβ isoforms

Anti-Cancer Drugs

Volumn 10, Issue 6, 1999, Pages 551-560

  Van Hille, B ^a   Perrin, D ^a   Hill, B T ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Catalytic cycle; DNA cleavage; Inhibitors; Religation; Topoisomerase II ; Topoisomerase II

Indexed keywords

ACLARUBICIN; AMSACRINE; ANTINEOPLASTIC AGENT; AZATOXIN; CAMPTOTHECIN; DACTINOMYCIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; RAZOXANE; UNCLASSIFIED DRUG;

ARTICLE; DNA CLEAVAGE; DNA SEQUENCE; PRIORITY JOURNAL;

EID: 0032842419     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199907000-00007     Document Type: Article

References (27)

1. 1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985; 54: 665-97.
2. 2. Osheroff N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmac Ther 1989; 41: 223-41.
3. 3. Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J 1994; 303: 681-95.
4. 4. Corbett AH, Osheroff N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplasic drugs. Chem Res Toxicol 1993; 6: 585-97.
5. 5. Chung TDY, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 1989; 86: 9431-5.
6. 6. Drake FH, Hofmann GA, Bartus HF, et al. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989; 28: 8154-60.
7. 7. Jensen S, Redwood CS, Jenkins JR, Andersen AH, Hickson ID. Human DNA topoisomerases IIα and IIα can functionally substitute for yeast TOP2 in chromosome segregation and recombination. Mol Gen Genet 1996; 252: 79-86.
8. 8. Grue P, Grasser A, Sehested M, et al. Essential mitotic functions of DNA topoisomerase IIα are not adopted by topoisomerase IIβ in human H69 cells. J Biol Chem 1998; 273: 33660-6.
9. 9. Turley H, Comley M, Houlbrook S, et al. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer 1997; 75: 1340-6.
10. 10. Sorensen BS, Sinding J, Andersen AH, Alsner J, Jense PB, Westergaard O. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. J Mol Biol 1992; 228: 778-86.
11. 11. Capranico G, Zunino F. Antitumor inhibitors of DNA topoisomerase. Curr Pharm Des 1995; 1: 1-14.
12. 12. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351-75.
13. 13. Capranico G, Zunino F, Kohn KW, Pommier Y. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry 1990; 29: 562-9.
14. 14. Pommier Y, Orr A, Kohn KW, Riou J-F. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene. Cancer Res, 1992; 52: 3125-30.
15. 15. Cornarotti M, Tinelli S, Willmore E, et al. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerase IIα (p170) and IIβ (p180). Mol Pharmacol 1996; 50: 1463-71.
16. 16. Marsh KL, Willmore E, Tinelli S, et al. Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms α and β. Biochem Pharmacol 1996; 52: 1675-585.
17. 17. Perrin D, van Hille B, Hill BT. Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II-interacting agents. Biochem Pharmacol 1998; 56: 503-7.
18. 18. Austin CA, Marsh KL, Wassermann RA, et al. Expression domain structure and enzymatic properties of an active recombinant human DNA topoisomerase IIβ. J Biol Chem 1995; 270: 15739-46.
19. 19. DeVita VT, Jr Hellman S, Rosenberg SA. Cancer: principles and practice of oncology, 4th edn. Philadelphia, PA: Lippincott 1993.
20. 20. Budman DR. Early studies of etoposide phosphate a water soluble prodrug. Semin Oncol 1996; 23: 8-14.
21. 21. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E, Demant EJF. Antagonistic effect of the cardioprotector (+)-12-bis(35-dioxopiperazinyl-1-YL)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 1993; 46: 389-93.
22. 22. Fox KR. Use of enzymatic and chemical probes to determine the effect of drug binding on local DNA structure. In: Hurley LH, ed. Advances in DNA sequence specific agents. Greenwich, CT: JAI Press 1992: 167-214.
23. 23. Petersen LN, Jensen PB, Sorensen BS, Engelholm SA, Spang-Thomsen M. Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage strand breaks and cytotoxicity induced by VP-16. Invest New Drugs 1994; 12: 289-97.
24. 24. Leteurtre F, Madalengoitia J, Orr A, et al. Rational design and molecular effects of a new topoisomerase II inhibitor azatoxin. Cancer Res 1992; 52: 4478-83.
25. 25. Capranico G, Palumbo M, Tinelli S, Mabilia M, Pozzan A, Zunino F. Conformational drug determination of the sequence-specificity of drug-stimulated topoisomerase II DNA cleavage. J Mol Biol 1994; 235: 1218-30.
26. 26. Yamashita Y, Kawada S-Z, Nakano H. Induction of mammalian topoisomerase II dependent DNA cleavage DNA by nonintercalative flavonoids genistein and orobol. Biochem Pharmacol 1990; 39: 737-44.
27. 27. Fesen M, Pommier Y. Mammalian topoisomerase II activity is modulated by the DNA minor groove binder distamycin in SV-40 DNA. J Biol Chem 1989; 264: 11354-9.